Snoring (medical term for snoring, snoring, sleep apnea syndrome) is a widespread sleep phenomenon, which most people currently think is commonplace and do not take it seriously, but in fact snoring is a major enemy of health. . So is sleep apnea a risk factor for CKD? Although the high prevalence of chronic kidney disease is closely related to the increasing prevalence of diabetes, hypertension, and obesity, sleep apnea and nocturnal hypoxemia also play an important role in the pathogenesis of chronic kidney disease and the course of renal failure. Recently, the potential impact of obstructive sleep apnea (OSA) on the progression of CKD disease has received increasing public attention. A number of studies have pointed to a possible bidirectional causal association between sleep apnea and kidney disease. Two pathophysiological mechanisms of CKD: glomerular hyperfiltration and chronic renal hypoxia, both lead to tubular interstitial damage and ultimately to end-stage renal disease (ESKD). Many studies have confirmed the association between sleep apnea and CKD. Sleep apnea and nocturnal hypoxemia often lead to decreased and impaired renal function, suggesting a strong link between sleep apnea, nocturnal hypoxemia and the pathogenesis leading to deterioration of renal function. Sleep apnea can lead to deterioration of renal function through multiple pathways, including: the direct effects of renal hypoxia and systemic and renal activation of the renin-angiotensin system. the rapid increase in the prevalence of CKD is often closely related to the increasing prevalence of diabetes, hypertension and obesity, but the high prevalence of these chronic diseases does not fully explain the increased prevalence of CKD. It is known that the prevalence of sleep apnea is high and often severe in patients with end-stage renal disease; this may be due to instability of the respiratory center and obstruction of the upper airway during sleep. Sleep apnea is also an important comorbidity in patients with end-stage renal disease, leading to daytime sleepiness and increased cardiovascular morbidity and mortality. The prevalence of sleep apnea has still seen a dramatic increase in the last 20 years. Sleep apnea contributes to the progression of renal disease and decreased renal function through the direct effects of renal hypoxia and the indirect effects of oxidative stress, endothelial dysfunction, inflammatory cytokine levels, sympathetic nerve activity, and increased systemic blood pressure levels. Overall, sleep apnea syndrome is common in patients with CKD and can lead to progression of renal disease. Nocturnal hypoxemia can act on the renin-angiotensin system or directly on the kidney, leading to the progression of renal disease through several pathways. Further studies are needed to clarify how specific treatments block these pathways and whether these treatments can actually improve clinical regression.